Exact Mass: 285.0573

Exact Mass Matches: 285.0573

Found 92 metabolites which its exact mass value is equals to given mass value 285.0573, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

   

MFCD00049038

5-Deoxy-5-chloroadenosine

C10H12ClN5O3 (285.0629)


   

Cladribine

(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

C10H12ClN5O3 (285.0629)


Cladribine is only found in individuals that have used or taken this drug. It is an antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. [PubChem]Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. Although the exact mechanism of action has not been fully determined, evidence shows that cladribine is phosphorylated by deoxycytidine kinase to the nucleotidecladribine triphosphate (CdATP; 2-chloro-2′-deoxyadenosine 5′-triphosphate), which accumulates and is incorporated into DNA in cells such as lymphocytes that contain high levels of deoxycytidine kinase and low levels of deoxynucleotidase, resulting in DNA strand breakage and inhibition of DNA synthesis and repair. High levels of CdATP also appear to inhibit ribonucleotide reductase, which leads to an imbalance in triphosphorylated deoxynucleotide (dNTP) pools and subsequent DNA strand breaks, inhibition of DNA synthesis and repair, nicotinamide adenine dinucleotide (NAD) and ATP depletion, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established. L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent D000970 - Antineoplastic Agents Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis[1][2].

   

7-Aminoclonazepam

7-amino-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2-ol

C15H12ClN3O (285.0669)


7-aminoclonazepam belongs to the family of Benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).

   

Faropenem

(+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid

C12H15NO5S (285.0671)


Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. It is available for oral use. Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms. The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (CID 636379 from PubChem) The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem, but company officials recently announced this name was rejected by the FDA.

   

2-Chloro-3'-deoxyadenosine

2-(6-amino-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol

C10H12ClN5O3 (285.0629)


   

5-(4-Fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole

5-(4-Fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole

C14H8FN3O3 (285.055)


   

2-Chloro-9-(2-deoxy-beta-D-arabinofuranosyl)adenine

5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

C10H12ClN5O3 (285.0629)


   

3H-1,4-Benzodiazepin-2-amine, 7-chloro-5-phenyl-, 4-oxide

7-chloro-2-imino-5-phenyl-3,4-dihydro-2H-1,4-benzodiazepin-4-ol

C15H12ClN3O (285.0669)


   
   
   
   

1-(3,4-dichlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine

1-(3,4-dichlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine

C11H13Cl2N5 (285.0548)


   

Actinomycinol

Actinomycinol

C15H11NO5 (285.0637)


   
   

Cladribine

Cladribine

C10H12ClN5O3 (285.0629)


L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent D000970 - Antineoplastic Agents CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2617; ORIGINAL_PRECURSOR_SCAN_NO 2616 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2634; ORIGINAL_PRECURSOR_SCAN_NO 2632 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2626; ORIGINAL_PRECURSOR_SCAN_NO 2625 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2623; ORIGINAL_PRECURSOR_SCAN_NO 2621 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2643; ORIGINAL_PRECURSOR_SCAN_NO 2642 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2641; ORIGINAL_PRECURSOR_SCAN_NO 2639 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5653; ORIGINAL_PRECURSOR_SCAN_NO 5650 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5671; ORIGINAL_PRECURSOR_SCAN_NO 5668 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5700; ORIGINAL_PRECURSOR_SCAN_NO 5699 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5680; ORIGINAL_PRECURSOR_SCAN_NO 5677 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5706; ORIGINAL_PRECURSOR_SCAN_NO 5702 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5693; ORIGINAL_PRECURSOR_SCAN_NO 5691 Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis[1][2].

   

7-Aminoclonazepam

7-Aminoclonazepam

C15H12ClN3O (285.0669)


   

8-Chloro-deoxyadenosine

8-Chloro-deoxyadenosine

C10H12Cl1N5O3 (285.0629)


   

2-Chloro-deoxyadenosine

2-Chloro-deoxyadenosine

C10H12Cl1N5O3 (285.0629)


   

2-(BENZOYLAMINO)-4-(METHYLSULFONYL)BUTANOIC ACID

2-(BENZOYLAMINO)-4-(METHYLSULFONYL)BUTANOIC ACID

C12H15NO5S (285.0671)


   

4-HYDROXY-1-[(4-METHYLPHENYL)SULFONYL]-2-PYRROLIDINECARBOXYLIC ACID

4-HYDROXY-1-[(4-METHYLPHENYL)SULFONYL]-2-PYRROLIDINECARBOXYLIC ACID

C12H15NO5S (285.0671)


   

3-AMINO-7-CHLORO-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE

3-AMINO-7-CHLORO-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE

C15H12ClN3O (285.0669)


   

1-(Pyridin-3-ylmethyl)piperazine trihydrochloride

1-(Pyridin-3-ylmethyl)piperazine trihydrochloride

C10H18Cl3N3 (285.0566)


   

1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxylic acid

1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxylic acid

C12H15NO5S (285.0671)


   

(2R,4S)-4-hydroxy-1-(4-methylphenyl)sulfonyl-pyrrolidine-2-carboxylate

(2R,4S)-4-hydroxy-1-(4-methylphenyl)sulfonyl-pyrrolidine-2-carboxylate

C12H15NO5S (285.0671)


   

4-(Methylsulfonyl)-3-morpholinobenzoic Acid

4-(Methylsulfonyl)-3-morpholinobenzoic Acid

C12H15NO5S (285.0671)


   

N-(2,4-DINITROPHENYL)-DL-THREONINE

N-(2,4-DINITROPHENYL)-DL-THREONINE

C10H11N3O7 (285.0597)


   
   

2-AMINO-6-CHLORO-9-(BETA-D-2-DEOXYRIBOFURANOSYL)PURINE

2-AMINO-6-CHLORO-9-(BETA-D-2-DEOXYRIBOFURANOSYL)PURINE

C10H12ClN5O3 (285.0629)


   

Ethyl 4-oxo-7-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylate

Ethyl 4-oxo-7-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylate

C13H10F3NO3 (285.0613)


   

Methyl 8-methyl-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-2-carboxylate

Methyl 8-methyl-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-2-carboxylate

C13H10F3NO3 (285.0613)


   

1-pyridin-3-ylmethyl-pyrrolidin-3-ylamine trihydrochloride

1-pyridin-3-ylmethyl-pyrrolidin-3-ylamine trihydrochloride

C10H18Cl3N3 (285.0566)


   

5-(2-Fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole

5-(2-Fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole

C14H8FN3O3 (285.055)


   

Isoxazole,3-(4-chlorophenyl)-5-(4-methoxyphenyl)-

Isoxazole,3-(4-chlorophenyl)-5-(4-methoxyphenyl)-

C16H12ClNO2 (285.0557)


   

1-[(4-chlorophenyl)methyl]-5-methylindole-2,3-dione

1-[(4-chlorophenyl)methyl]-5-methylindole-2,3-dione

C16H12ClNO2 (285.0557)


   

POTASSIUM [2-(BENZYLOXYCARBONYLAMINO)ETHYL] TRIFLUOROBORATE

POTASSIUM [2-(BENZYLOXYCARBONYLAMINO)ETHYL] TRIFLUOROBORATE

C10H12BF3KNO2 (285.055)


   

Ethyl 4-hydroxy-8-(trifluoromethyl)quinoline-3-carboxylate

Ethyl 4-hydroxy-8-(trifluoromethyl)quinoline-3-carboxylate

C13H10F3NO3 (285.0613)


   

dnp-l-threonine

dnp-l-threonine

C10H11N3O7 (285.0597)


   

N-Benzanilide-4,4-dicarboxylic acid

N-Benzanilide-4,4-dicarboxylic acid

C15H11NO5 (285.0637)


   

1-Butylpyridinium trifluoromethanesulfonate

1-Butylpyridinium trifluoromethanesulfonate

C10H14F3NO3S (285.0646)


   

3-Quinolinecarboxylicacid, 4-hydroxy-7-(trifluoromethyl)-, ethyl ester

3-Quinolinecarboxylicacid, 4-hydroxy-7-(trifluoromethyl)-, ethyl ester

C13H10F3NO3 (285.0613)


   

2-[4-(5-Bromo-2-pyridinyl)-1-piperazinyl]ethanol

2-[4-(5-Bromo-2-pyridinyl)-1-piperazinyl]ethanol

C11H16BrN3O (285.0477)


   

7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylic acid

7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylic acid

C15H11NO5 (285.0637)


   

2-CARBOXY-PHTHALANIC ACID

2-CARBOXY-PHTHALANIC ACID

C15H11NO5 (285.0637)


   

Ethyl 4-hydroxy-2-(trifluoromethyl)quinoline-3-carboxylate

Ethyl 4-hydroxy-2-(trifluoromethyl)quinoline-3-carboxylate

C13H10F3NO3 (285.0613)


   

Ethyl 5-(aminomethyl)-1,3,4-oxadiazole-2-carboxylate

Ethyl 5-(aminomethyl)-1,3,4-oxadiazole-2-carboxylate

C8H10F3N3O5 (285.0573)


   

ethyl 2-(4-acetamidophenyl)sulfonylacetate

ethyl 2-(4-acetamidophenyl)sulfonylacetate

C12H15NO5S (285.0671)


   

4-(Methylsulfonyl)-2-morpholinobenzoic Acid

4-(Methylsulfonyl)-2-morpholinobenzoic Acid

C12H15NO5S (285.0671)


   

4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOICACID

4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOICACID

C12H15NO5S (285.0671)


   

METHYL 2-(MORPHOLINOSULFONYL)BENZOATE

METHYL 2-(MORPHOLINOSULFONYL)BENZOATE

C12H15NO5S (285.0671)


   

METHYL 3-METHYL-5-[4-(TRIFLUOROMETHYL)PHENYL]ISOXAZOLE-4-CARBOXYLATE

METHYL 3-METHYL-5-[4-(TRIFLUOROMETHYL)PHENYL]ISOXAZOLE-4-CARBOXYLATE

C13H10F3NO3 (285.0613)


   

5-BROMO-N-(2-MORPHOLINOETHYL)PYRIDIN-2-AMINE

5-BROMO-N-(2-MORPHOLINOETHYL)PYRIDIN-2-AMINE

C11H16BrN3O (285.0477)


   

ETHYL 5-(4-(TRIFLUOROMETHYL)PHENYL)ISOXAZOLE-3-CARBOXYLATE

ETHYL 5-(4-(TRIFLUOROMETHYL)PHENYL)ISOXAZOLE-3-CARBOXYLATE

C13H10F3NO3 (285.0613)


   

m-chlorophenoxysilatrane

m-chlorophenoxysilatrane

C12H16ClNO3Si (285.0588)


   

Ethyl 4-hydroxy-6-(trifluoromethyl)quinoline-3-carboxylate

Ethyl 4-hydroxy-6-(trifluoromethyl)quinoline-3-carboxylate

C13H10F3NO3 (285.0613)


   

4-[(TETRAHYDRO-FURAN-2-YLMETHYL)-SULFAMOYL]-BENZOIC ACID

4-[(TETRAHYDRO-FURAN-2-YLMETHYL)-SULFAMOYL]-BENZOIC ACID

C12H15NO5S (285.0671)


   

2-Azido-1,3-dimethylimidazolinium hexafluorophosphate

2-Azido-1,3-dimethylimidazolinium hexafluorophosphate

C5H10F6N5P (285.0578)


   

5-(3-TRIFLUOROMETHYLPHENYL)-ISOXAZOLE-3-CARBOXYLIC ACID ETHYL ESTER

5-(3-TRIFLUOROMETHYLPHENYL)-ISOXAZOLE-3-CARBOXYLIC ACID ETHYL ESTER

C13H10F3NO3 (285.0613)


   

1-(5-Bromo-2-fluorobenzyl)-4-methylpiperidine

1-(5-Bromo-2-fluorobenzyl)-4-methylpiperidine

C13H17BrFN (285.0528)


   

1-[2-(4-CHLOROPHENYL)-7-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-6-YL]ETHAN-1-ONE

1-[2-(4-CHLOROPHENYL)-7-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-6-YL]ETHAN-1-ONE

C15H12ClN3O (285.0669)


   

Adenosine,8-chloro-2-deoxy- (9CI)

Adenosine,8-chloro-2-deoxy- (9CI)

C10H12ClN5O3 (285.0629)


   

10-Methoxyiminostilbene-5-carbonylchloride

10-Methoxyiminostilbene-5-carbonylchloride

C16H12ClNO2 (285.0557)


   

5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

C10H12ClN5O3 (285.0629)


   

5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide

5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide

C14H11N3O2S (285.0572)


   

5-Phosphoribosylglycineamide

5-Phosphoribosylglycineamide

C7H14N2O8P- (285.0488)


   

gentisate 5-O-beta-D-xylopyranoside

gentisate 5-O-beta-D-xylopyranoside

C12H13O8- (285.061)


D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates

   

(2S,4R,5R,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-4,5-dihydroxy-3-oxooxane-2-carboxylic acid

(2S,4R,5R,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-4,5-dihydroxy-3-oxooxane-2-carboxylic acid

C10H11N3O7 (285.0597)


   

N(1)-(5-phospho-D-ribosyl)glycinamide(1-)

N(1)-(5-phospho-D-ribosyl)glycinamide(1-)

C7H14N2O8P- (285.0488)


Conjugate base of N(1)-(5-phospho-D-ribosyl)glycinamide. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

N-(3-bicyclo[2.2.1]heptanyl)-4-chlorobenzenesulfonamide

N-(3-bicyclo[2.2.1]heptanyl)-4-chlorobenzenesulfonamide

C13H16ClNO2S (285.059)


   

7-Chloro-2-methyl-3-(pyridin-4-ylmethyl)quinazolin-4-one

7-Chloro-2-methyl-3-(pyridin-4-ylmethyl)quinazolin-4-one

C15H12ClN3O (285.0669)


   

N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-thiophenecarboxamide

N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-thiophenecarboxamide

C14H11N3O2S (285.0572)


   

6-chloro-4-hydroxy-3-(phenylmethyl)-1H-quinolin-2-one

6-chloro-4-hydroxy-3-(phenylmethyl)-1H-quinolin-2-one

C16H12ClNO2 (285.0557)


   

(3R)-5-(6-amino-2-chloro-9-purinyl)-2-(hydroxymethyl)-3-oxolanol

(3R)-5-(6-amino-2-chloro-9-purinyl)-2-(hydroxymethyl)-3-oxolanol

C10H12ClN5O3 (285.0629)


   

6beta-[(S)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid

6beta-[(S)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid

C12H15NO5S (285.0671)


   

(5R)-6-(1-hydroxyethyl)-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(5R)-6-(1-hydroxyethyl)-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C12H15NO5S (285.0671)


   

2-hydroxyphenyl beta-D-glucopyranosiduronate

2-hydroxyphenyl beta-D-glucopyranosiduronate

C12H13O8- (285.061)


   

(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-(oxolan-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-(oxolan-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C12H15NO5S (285.0671)


   

(5R,6S)-6-[(1S)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(5R,6S)-6-[(1S)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C12H15NO5S (285.0671)


   

5-Chloro-5-deoxyadenosine

5-Chloro-5-deoxyadenosine

C10H12ClN5O3 (285.0629)


   

6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid

6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid

C12H15NO5S (285.0671)


   
   

catechol beta-D-glucuronide(1-)

catechol beta-D-glucuronide(1-)

C12H13O8 (285.061)


A carbohydrate acid derivative anion resulting from the removal of a proton from the carboxy group of catechol beta-D-glucuronide.

   

SIRT7 inhibitor 97491

SIRT7 inhibitor 97491

C15H12ClN3O (285.0669)


SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway.[1].

   

(2r)-2,3-bis(formyloxy)propoxy(2-(methylamino)ethoxy)phosphinic acid

(2r)-2,3-bis(formyloxy)propoxy(2-(methylamino)ethoxy)phosphinic acid

C8H16NO8P (285.0614)


   

5-hydroxy-7-methoxy-3-methyl-2h-cyclohexa[g]isoquinoline-6,9,10-trione

5-hydroxy-7-methoxy-3-methyl-2h-cyclohexa[g]isoquinoline-6,9,10-trione

C15H11NO5 (285.0637)


   

4-hydroxy-2,3-dimethoxybenzo[g]quinoline-5,10-dione

4-hydroxy-2,3-dimethoxybenzo[g]quinoline-5,10-dione

C15H11NO5 (285.0637)


   

2,6-dihydroxy-3-methoxy-4-methylbenzo[g]quinoline-5,10-dione

2,6-dihydroxy-3-methoxy-4-methylbenzo[g]quinoline-5,10-dione

C15H11NO5 (285.0637)


   

methyl 2-methoxy-1,5-dioxopyrrolo[1,2-a]quinoline-4-carboxylate

methyl 2-methoxy-1,5-dioxopyrrolo[1,2-a]quinoline-4-carboxylate

C15H11NO5 (285.0637)


   

7,9-dihydroxy-6-methoxy-3-methylbenzo[g]isoquinoline-5,10-dione

7,9-dihydroxy-6-methoxy-3-methylbenzo[g]isoquinoline-5,10-dione

C15H11NO5 (285.0637)


   

5,10-dihydroxy-7-methoxy-3-methylcyclohexa[g]isoquinoline-6,9-dione

5,10-dihydroxy-7-methoxy-3-methylcyclohexa[g]isoquinoline-6,9-dione

C15H11NO5 (285.0637)


   

4-[(1z)-2-hydroxyethenyl]phenyl (3z)-3-(hydroxyimino)-4-oxocyclohexa-1,5-diene-1-carboxylate

4-[(1z)-2-hydroxyethenyl]phenyl (3z)-3-(hydroxyimino)-4-oxocyclohexa-1,5-diene-1-carboxylate

C15H11NO5 (285.0637)


   

4-(2-hydroxyethenyl)phenyl 4-hydroxy-3-nitrosobenzoate

4-(2-hydroxyethenyl)phenyl 4-hydroxy-3-nitrosobenzoate

C15H11NO5 (285.0637)